title: [Is morphine still the analgesic of choice in acute myocardial infarction?].
abstract: Chest pain is the most common symptom of patients who present with ischemic heart disease. Morphine has traditionally been the drug of choice for managing chest pain in acute coronary syndrome (ACS) due to its high analgesic potency, though its physiological effects are poorly understood. Routinely used for managing chest pain, morphine is recommended in the 2002 guidelines of the American College of Cardiology/American Heart Association. This recommendation, however, is not based on a high level of scientific evidence but on expert opinion. Studies have found both for and against the use of morphine in ACS, suggesting that its benefits are perhaps not altogether clear. This review examines the pathophysiological effects of morphine and their cardiac implications, with special attention to a possible negative effect on ACS. We reviewed articles in the MEDLINE database from 1982 to 2006.
authors.affiliation: Servicio de Anestesiología y Reanimación, Hospital General Universitario Vall d'Hebron, Barcelona. albimar23@yahoo.es
authors.forename: A
authors.initials: A
authors.lastname: Hernández
authors.forename: M A
authors.initials: MA
authors.lastname: Sola
authors.forename: B
authors.initials: B
authors.lastname: Domínguez
authors.forename: M I
authors.initials: MI
authors.lastname: Rochera
authors.forename: P
authors.initials: P
authors.lastname: Bascuñana
authors.forename: V
authors.initials: V
authors.lastname: Gancedo
mesh_terms: D000572:American Heart Association; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy* / Q000209:etiology; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D016232:Endothelins / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D015394:Molecular Structure; D009020:Morphine / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy; D009569:Nitric Oxide / Q000378:metabolism; D005996:Nitroglycerin / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000502:physiology; D014481:United States; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000701:Analgesics, Opioid; D002316:Cardiotonic Agents; D016232:Endothelins; D017450:Receptors, Opioid, mu; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D014665:Vasodilator Agents; D009569:Nitric Oxide; D009020:Morphine; D005996:Nitroglycerin